US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ashland

53.61

+2.805.51%

Post-market: 53.610.00000.00%19:52 EDT

Volume:815.23K

Turnover:43.23M

Market Cap:2.45B

PE:-3.54

High:53.75

Open:51.57

Low:51.15

Close:50.81

52wk High:65.65

52wk Low:45.21

Shares:45.76M

Float Shares:41.77M

Volume Ratio:1.07

T/O Rate:1.95%

Dividend:1.65

Dividend Rate:3.08%

EPS(TTM):-15.1257

EPS(LYR):-18.3696

ROE:-29.98%

ROA:2.09%

PB:1.31

PE(LYR):-2.92

Loading ...

Overview Company News Filings

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Why Is Arcellx Stock Surging Today?

Syndax Reports Strong Data for AML Combination Therapy

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Vertex's Gene Therapy Works In Children With Blood Disorders

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Adaptive Biotechnologies (ADPT): Valuation Check After ASH clonoSEQ Data Spotlight and Q3 Earnings Beat

Simply Wall St.

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features

Benzinga_recent_news

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASH/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"Ashland","latestPrice":53.61,"timestamp":1774468800000,"preClose":50.81,"halted":0,"volume":815234,"hourTrading":{"tag":"盘后","latestPrice":53.61,"preClose":53.61,"latestTime":"19:52 EDT","volume":15678,"amount":840498.48,"timestamp":1774482777103,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.05510726234993106,"floatShares":41773472,"shares":45762099,"eps":-15.125683,"marketStatus":"Closed","change":2.8,"latestTime":"03-25 16:00:00 EDT","open":51.57,"high":53.75,"low":51.15,"amount":43230147.0286,"amplitude":0.051171,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-15.125683,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":50.81,"dividendRate":0.030782,"preHourTrading":{"tag":"盘前","latestPrice":51,"preClose":50.81,"latestTime":"09:04 EDT","volume":31,"amount":1584.260084,"timestamp":1774443856068,"change":0.19,"changeRate":0.003739,"amplitude":0.006101},"postHourTrading":{"tag":"盘后","latestPrice":53.61,"preClose":53.61,"latestTime":"19:52 EDT","volume":15678,"amount":840498.48,"timestamp":1774482777103,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.070311,"impliedVol":0.5063,"impliedVolPercentile":0.9243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","floatShares":41773472,"roa":"2.09%","roe":"-29.98%","lyrEps":-18.369565,"volumeRatio":1.070311,"shares":45762099,"dividePrice":1.6502,"high":53.75,"amplitude":0.051171,"preClose":50.81,"low":51.15,"week52Low":45.21,"pbRate":"1.31","psRate":"1.36","week52High":65.645,"institutionHeld":0.8513,"latestPrice":53.61,"eps":-15.125683,"divideRate":0.030782,"volume":815234,"delay":0,"ttmEps":-15.125683,"open":51.57,"prevYearClose":58.67,"prevWeekClose":48.81,"prevMonthClose":62.36,"prevQuarterClose":58.67,"fiveDayClose":50.09,"twentyDayClose":62.22,"sixtyDayClose":59.7,"dividendPayoutRate":0.4581065874857458,"dividendFrequency":"Q","dividendGrowthYears":7,"dividendGrowthRate":0.037974683544303826,"fiveYearAvgDividendRate":0.01932116730388857},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASH\",params:#limit:5,,,undefined,":[{"date":"2026-02-27","symbol":"ASH","amount":0.415,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-01","defaultRemindTime":1772202600000,"name":"Ashland","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-15","payableDate":"2026-03-01","currency":"USD","dateTimestamp":1772168400000,"payDate":"2026-03-15"},{"market":"US","date":"2026-02-02","symbol":"ASH","fiscalQuarterEnding":"2025/12","expectedEps":0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1770008400000,"reportTimeType":"post","actualEps":0.26},{"date":"2025-12-01","symbol":"ASH","amount":0.415,"announcedDate":"2025-11-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-01","defaultRemindTime":1764599400000,"name":"Ashland","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-15","payableDate":"2025-12-01","currency":"USD","dateTimestamp":1764565200000,"payDate":"2025-12-15"},{"market":"US","date":"2025-11-04","symbol":"ASH","fiscalQuarterEnding":"2025/09","expectedEps":1.17,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":1.08},{"date":"2025-08-29","symbol":"ASH","amount":0.415,"announcedDate":"2025-08-08","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-01","defaultRemindTime":1756474200000,"name":"Ashland","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-15","payableDate":"2025-09-01","currency":"USD","dateTimestamp":1756440000000,"payDate":"2025-09-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASH\",market:\"US\",,,undefined,":[{"executeDate":"2016-06-01","recordDate":"2016-06-03","paymentDate":"2016-06-15","value":0.39,"currency":"USD"},{"executeDate":"2016-08-17","recordDate":"2016-08-19","paymentDate":"2016-09-15","value":0.39,"currency":"USD"},{"executeDate":"2016-11-29","recordDate":"2016-12-01","paymentDate":"2016-12-15","value":0.39,"currency":"USD"},{"executeDate":"2017-02-27","recordDate":"2017-03-01","paymentDate":"2017-03-15","value":0.39,"currency":"USD"},{"executeDate":"2017-05-30","recordDate":"2017-06-01","paymentDate":"2017-06-15","value":0.225,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2308,"buy":0.4615,"hold":0.3077,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4615,"analysts":13,"updateTime":1765857600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASH","date":"2026-03-24","current":-3.544303,"percent":0.164043,"low":-152.607239,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"high":41.666396,"avg":6.974779,"sd":34.703928,"marketCap":2284443982},"quantilePoints":[{"date":"2021-03-26","current":-11.298674,"twenty":-41.685517,"median":16.565507,"eighty":45.060758,"marketCap":5468558354},{"date":"2021-04-01","current":-11.32625,"twenty":-41.685517,"median":16.544159,"eighty":45.032615,"marketCap":5481905179},{"date":"2021-04-09","current":-11.130711,"twenty":-41.766144,"median":16.513421,"eighty":45.025182,"marketCap":5387264054},{"date":"2021-04-16","current":-11.373882,"twenty":-41.766144,"median":16.49824,"eighty":44.88663,"marketCap":5504958787},{"date":"2021-04-23","current":-11.615799,"twenty":-41.766144,"median":16.458163,"eighty":44.798223,"marketCap":5622046845},{"date":"2021-04-30","current":37.652621,"twenty":-41.766144,"median":16.458163,"eighty":44.763306,"marketCap":5233714269},{"date":"2021-05-07","current":38.556703,"twenty":-41.766144,"median":16.48927,"eighty":44.763306,"marketCap":5359381692},{"date":"2021-05-14","current":38.897371,"twenty":-41.766144,"median":16.508117,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-21","current":38.897371,"twenty":-41.766144,"median":16.532217,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-28","current":41.421813,"twenty":-41.766144,"median":16.539302,"eighty":44.763306,"marketCap":5757632076},{"date":"2021-06-04","current":41.177231,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5723635092},{"date":"2021-06-11","current":40.923913,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5688423930},{"date":"2021-06-18","current":38.067538,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5291387724},{"date":"2021-06-25","current":38.72267,"twenty":-41.766144,"median":16.559996,"eighty":44.763306,"marketCap":5382451074},{"date":"2021-07-02","current":38.32959,"twenty":-41.766144,"median":16.589527,"eighty":44.763306,"marketCap":5327813064},{"date":"2021-07-09","current":38.399471,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5337526488},{"date":"2021-07-16","current":37.713766,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5242213515},{"date":"2021-07-23","current":38.233504,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5314457106},{"date":"2021-07-30","current":28.544675,"twenty":-41.766144,"median":16.63409,"eighty":44.763306,"marketCap":5166586254},{"date":"2021-08-06","current":28.329928,"twenty":-41.766144,"median":16.642592,"eighty":44.763306,"marketCap":5127716909},{"date":"2021-08-13","current":29.118455,"twenty":-41.766144,"median":16.707431,"eighty":44.763306,"marketCap":5270440286},{"date":"2021-08-20","current":28.051427,"twenty":-41.766144,"median":16.798988,"eighty":44.763306,"marketCap":5077308227},{"date":"2021-08-27","current":29.259383,"twenty":-41.766144,"median":16.876011,"eighty":44.763306,"marketCap":5295948294},{"date":"2021-09-03","current":31.51759,"twenty":-41.685517,"median":16.928602,"eighty":44.762757,"marketCap":5704683753},{"date":"2021-09-10","current":31.051184,"twenty":-41.685517,"median":16.94157,"eighty":44.762757,"marketCap":5620264394},{"date":"2021-09-17","current":30.272724,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5479363017},{"date":"2021-09-24","current":31.121649,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5633018398},{"date":"2021-10-01","current":30.59149,"twenty":-41.685517,"median":19.684212,"eighty":44.762757,"marketCap":5537059701},{"date":"2021-10-08","current":31.071317,"twenty":-41.685517,"median":19.787677,"eighty":44.762757,"marketCap":5623908395},{"date":"2021-10-15","current":32.124923,"twenty":-41.685517,"median":19.83941,"eighty":44.762757,"marketCap":5814611120},{"date":"2021-10-22","current":32.826209,"twenty":-41.685517,"median":19.917009,"eighty":44.762757,"marketCap":5941543826},{"date":"2021-10-29","current":32.21552,"twenty":-41.604889,"median":19.999764,"eighty":44.762207,"marketCap":5831009125},{"date":"2021-11-05","current":32.916806,"twenty":-41.604889,"median":20.15896,"eighty":44.762207,"marketCap":5957941831},{"date":"2021-11-12","current":29.342491,"twenty":-41.604889,"median":20.28364,"eighty":44.762207,"marketCap":6455347984},{"date":"2021-11-19","current":30.162391,"twenty":-41.604889,"median":20.500749,"eighty":44.762207,"marketCap":6635726039},{"date":"2021-11-26","current":26.923508,"twenty":-41.604889,"median":20.528215,"eighty":44.762207,"marketCap":5923171764},{"date":"2021-12-03","current":26.411959,"twenty":-41.604889,"median":20.552965,"eighty":44.762207,"marketCap":5810630932},{"date":"2021-12-10","current":27.165993,"twenty":-41.604889,"median":20.676932,"eighty":44.762207,"marketCap":5976518382},{"date":"2021-12-17","current":26.837476,"twenty":-41.604889,"median":20.708356,"eighty":44.762207,"marketCap":5904244736},{"date":"2021-12-23","current":26.982334,"twenty":-41.604889,"median":20.728755,"eighty":44.762207,"marketCap":5936113430},{"date":"2021-12-31","current":27.848893,"twenty":-41.604889,"median":20.764302,"eighty":44.762207,"marketCap":6126756513},{"date":"2022-01-07","current":26.876277,"twenty":-41.524262,"median":20.796751,"eighty":44.761658,"marketCap":5912780993},{"date":"2022-01-14","current":27.341891,"twenty":-41.524262,"median":20.868148,"eighty":44.761658,"marketCap":6015216083},{"date":"2022-01-21","current":25.013821,"twenty":-41.524262,"median":20.917445,"eighty":44.761658,"marketCap":5503040636},{"date":"2022-01-28","current":24.677544,"twenty":-41.524262,"median":20.980342,"eighty":44.761658,"marketCap":5429059738},{"date":"2022-02-04","current":25.572734,"twenty":-41.443634,"median":21.023702,"eighty":44.761108,"marketCap":5421419569},{"date":"2022-02-11","current":25.553938,"twenty":-41.443634,"median":21.065338,"eighty":44.761108,"marketCap":5417434905},{"date":"2022-02-18","current":25.494866,"twenty":-41.443634,"median":21.115412,"eighty":44.761108,"marketCap":5404911676},{"date":"2022-02-25","current":25.29617,"twenty":-41.443634,"median":21.157984,"eighty":44.761108,"marketCap":5362788089},{"date":"2022-03-04","current":23.572347,"twenty":-41.443634,"median":21.240692,"eighty":44.761108,"marketCap":4997337504},{"date":"2022-03-11","current":23.66901,"twenty":-41.443634,"median":21.332705,"eighty":44.761108,"marketCap":5017830061},{"date":"2022-03-18","current":25.352557,"twenty":-41.443634,"median":21.402701,"eighty":44.761108,"marketCap":5374742080},{"date":"2022-03-25","current":26.448071,"twenty":-41.443634,"median":21.507199,"eighty":44.761108,"marketCap":5606991049},{"date":"2022-04-01","current":26.544734,"twenty":-41.443634,"median":21.611248,"eighty":44.761108,"marketCap":5627483605},{"date":"2022-04-08","current":26.703154,"twenty":-41.443634,"median":21.681627,"eighty":44.761108,"marketCap":5661068628},{"date":"2022-04-14","current":28.520955,"twenty":-41.443634,"median":21.86021,"eighty":44.761108,"marketCap":6046442530},{"date":"2022-04-22","current":27.734226,"twenty":-41.443634,"median":22.114023,"eighty":44.761108,"marketCap":5879655893},{"date":"2022-04-29","current":5.98168,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5724467780},{"date":"2022-05-06","current":5.79477,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5545595204},{"date":"2022-05-13","current":5.627805,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5385809640},{"date":"2022-05-20","current":5.695617,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5450705483},{"date":"2022-05-27","current":6.155649,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5890955748},{"date":"2022-06-03","current":6.053281,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5792989652},{"date":"2022-06-10","current":5.809521,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5559711268},{"date":"2022-06-17","current":5.398352,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5166223136},{"date":"2022-06-24","current":5.835537,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5584608729},{"date":"2022-07-01","current":5.86325,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5611129938},{"date":"2022-07-08","current":5.737128,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5490431377},{"date":"2022-07-15","current":5.58499,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5344835356},{"date":"2022-07-22","current":5.922634,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5667961098},{"date":"2022-07-29","current":5.951187,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5439385116},{"date":"2022-08-05","current":6.14725,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5618586516},{"date":"2022-08-12","current":6.304219,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5762055916},{"date":"2022-08-19","current":6.275787,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5736069006},{"date":"2022-08-26","current":6.098679,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5574192212},{"date":"2022-09-02","current":5.884253,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5378207598},{"date":"2022-09-09","current":6.054846,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5534129059},{"date":"2022-09-16","current":5.848121,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5345182567},{"date":"2022-09-23","current":5.752755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5258018139},{"date":"2022-09-30","current":5.625403,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5141618438},{"date":"2022-10-07","current":5.617703,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5134580316},{"date":"2022-10-14","current":5.641396,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5156236075},{"date":"2022-10-21","current":5.922755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5413398206},{"date":"2022-10-28","current":6.27401,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5734444824},{"date":"2022-11-04","current":5.909724,"twenty":-41.524262,"median":21.695313,"eighty":44.761658,"marketCap":5401487538},{"date":"2022-11-11","current":6.292902,"twenty":-41.524262,"median":21.556282,"eighty":44.761658,"marketCap":5833519919},{"date":"2022-11-18","current":6.534105,"twenty":-41.524262,"median":9.134384,"eighty":44.761658,"marketCap":6057115624},{"date":"2022-11-25","current":6.524573,"twenty":-41.524262,"median":9.120072,"eighty":44.761658,"marketCap":6048278877},{"date":"2022-12-02","current":6.634386,"twenty":-41.524262,"median":9.077138,"eighty":44.761658,"marketCap":6150076230},{"date":"2022-12-09","current":6.425327,"twenty":-41.524262,"median":9.031818,"eighty":44.761658,"marketCap":5956278049},{"date":"2022-12-16","current":6.216944,"twenty":-41.524262,"median":8.981727,"eighty":44.761658,"marketCap":5763107329},{"date":"2022-12-23","current":6.332842,"twenty":-41.524262,"median":8.929251,"eighty":44.761658,"marketCap":5870544977},{"date":"2022-12-30","current":6.29421,"twenty":-41.524262,"median":8.870812,"eighty":44.761658,"marketCap":5834732428},{"date":"2023-01-06","current":6.238017,"twenty":-41.524262,"median":8.723665,"eighty":44.669031,"marketCap":5782641447},{"date":"2023-01-13","current":6.570492,"twenty":-41.524262,"median":8.558011,"eighty":44.528495,"marketCap":6090846415},{"date":"2023-01-20","current":6.436448,"twenty":-41.524262,"median":8.531792,"eighty":44.433823,"marketCap":5966587722},{"date":"2023-01-27","current":6.301234,"twenty":-41.524262,"median":8.3296,"eighty":44.14834,"marketCap":5841243800},{"date":"2023-02-03","current":6.219087,"twenty":-40.702575,"median":8.3296,"eighty":44.14834,"marketCap":5715340826},{"date":"2023-02-10","current":6.142315,"twenty":-11.558641,"median":8.3296,"eighty":44.14834,"marketCap":5644787763},{"date":"2023-02-17","current":6.10452,"twenty":-11.342294,"median":8.3296,"eighty":44.14834,"marketCap":5610053948},{"date":"2023-02-24","current":6.038378,"twenty":-11.297421,"median":8.3296,"eighty":44.14834,"marketCap":5549269770},{"date":"2023-03-03","current":6.122827,"twenty":-11.1811,"median":8.3296,"eighty":44.14834,"marketCap":5626878140},{"date":"2023-03-10","current":5.75019,"twenty":-11.13773,"median":8.3296,"eighty":44.14834,"marketCap":5284424426},{"date":"2023-03-17","current":5.610229,"twenty":-11.066032,"median":8.3296,"eighty":44.14834,"marketCap":5155800765},{"date":"2023-03-24","current":5.809835,"twenty":-10.976285,"median":8.3296,"eighty":44.14834,"marketCap":5339238729},{"date":"2023-03-31","current":6.065544,"twenty":-10.897567,"median":8.324965,"eighty":44.139273,"marketCap":5574234700},{"date":"2023-04-06","current":5.988772,"twenty":-10.820856,"median":8.324965,"eighty":44.139273,"marketCap":5503681637},{"date":"2023-04-14","current":6.134638,"twenty":-10.775982,"median":8.3296,"eighty":44.14834,"marketCap":5637732457},{"date":"2023-04-21","current":6.151764,"twenty":-10.730374,"median":8.3296,"eighty":44.14834,"marketCap":5653471217},{"date":"2023-04-27","current":5.856489,"twenty":-10.606264,"median":8.340928,"eighty":44.166474,"marketCap":5382113282},{"date":"2023-05-05","current":20.861975,"twenty":-10.43882,"median":8.452838,"eighty":44.175541,"marketCap":4693944269},{"date":"2023-05-12","current":20.287633,"twenty":-10.336151,"median":8.558011,"eighty":44.182524,"marketCap":4564717446},{"date":"2023-05-19","current":21.14158,"twenty":-10.102877,"median":8.693871,"eighty":44.189507,"marketCap":4756855455},{"date":"2023-05-26","current":20.227136,"twenty":-9.78508,"median":8.870812,"eighty":44.196491,"marketCap":4551105489},{"date":"2023-06-02","current":19.892072,"twenty":-9.536436,"median":8.929251,"eighty":44.196491,"marketCap":4475716188},{"date":"2023-06-09","current":20.206194,"twenty":-9.454384,"median":8.98113,"eighty":44.203474,"marketCap":4546393658},{"date":"2023-06-16","current":20.073565,"twenty":-9.376314,"median":9.018699,"eighty":44.210457,"marketCap":4516552059},{"date":"2023-06-23","current":19.475569,"twenty":-9.301666,"median":9.056863,"eighty":44.224123,"marketCap":4382003099},{"date":"2023-06-29","current":19.508145,"twenty":-9.246426,"median":9.092642,"eighty":44.237789,"marketCap":4389332615},{"date":"2023-07-05","current":20.315555,"twenty":-9.193781,"median":9.114705,"eighty":44.251456,"marketCap":4570999888},{"date":"2023-07-14","current":20.455165,"twenty":-9.060547,"median":9.163604,"eighty":44.278788,"marketCap":4602412096},{"date":"2023-07-20","current":21.216038,"twenty":-8.93818,"median":19.183552,"eighty":44.278788,"marketCap":4773608633},{"date":"2023-07-28","current":19.591649,"twenty":4.319692,"median":19.750135,"eighty":44.283744,"marketCap":4682404042},{"date":"2023-08-04","current":19.289348,"twenty":4.38581,"median":19.591649,"eighty":44.129229,"marketCap":4610154209},{"date":"2023-08-11","current":19.13927,"twenty":4.38581,"median":19.482306,"eighty":43.956729,"marketCap":4574285498},{"date":"2023-08-18","current":18.466062,"twenty":4.38581,"median":19.154278,"eighty":43.542383,"marketCap":4413388708},{"date":"2023-08-25","current":18.088722,"twenty":4.38581,"median":18.641868,"eighty":43.319191,"marketCap":4323204519},{"date":"2023-08-31","current":18.781226,"twenty":4.38581,"median":18.466062,"eighty":42.973946,"marketCap":4488713001},{"date":"2023-09-08","current":17.87218,"twenty":4.380867,"median":18.294543,"eighty":42.623722,"marketCap":4271451093},{"date":"2023-09-13","current":17.293307,"twenty":4.378395,"median":18.166977,"eighty":42.388429,"marketCap":4133100350},{"date":"2023-09-22","current":18.005107,"twenty":4.319692,"median":17.86146,"eighty":42.077012,"marketCap":4303220523},{"date":"2023-09-29","current":17.479833,"twenty":4.263461,"median":17.50556,"eighty":41.816324,"marketCap":4177680034},{"date":"2023-10-06","current":17.087485,"twenty":4.263461,"median":17.293307,"eighty":41.73771,"marketCap":4083908975},{"date":"2023-10-13","current":16.418565,"twenty":4.263461,"median":16.945983,"eighty":41.577207,"marketCap":3924037005},{"date":"2023-10-20","current":16.294214,"twenty":4.207231,"median":16.495748,"eighty":41.332109,"marketCap":3894317216},{"date":"2023-10-27","current":16.257767,"twenty":-1.056217,"median":16.28671,"eighty":41.192954,"marketCap":3885606243},{"date":"2023-11-03","current":16.332806,"twenty":-6.207204,"median":16.153784,"eighty":40.948113,"marketCap":3903540598},{"date":"2023-11-10","current":15.616718,"twenty":-6.207204,"median":15.881499,"eighty":40.817223,"marketCap":3732395605},{"date":"2023-11-17","current":16.390693,"twenty":-6.207204,"median":15.574911,"eighty":40.340898,"marketCap":3917375673},{"date":"2023-11-24","current":22.827913,"twenty":-6.207204,"median":15.574911,"eighty":39.96161,"marketCap":4063368468},{"date":"2023-12-01","current":23.015098,"twenty":-8.782697,"median":15.533103,"eighty":39.312288,"marketCap":4096687371},{"date":"2023-12-07","current":23.654406,"twenty":-6.207204,"median":15.574911,"eighty":38.926597,"marketCap":4210484243},{"date":"2023-12-15","current":24.893249,"twenty":-8.782697,"median":15.533103,"eighty":38.72267,"marketCap":4430998377},{"date":"2023-12-22","current":24.325418,"twenty":-8.782697,"median":15.533103,"eighty":38.648421,"marketCap":4329924480},{"date":"2023-12-29","current":24.225549,"twenty":-8.789917,"median":12.47951,"eighty":38.641433,"marketCap":4312147664},{"date":"2024-01-05","current":22.661874,"twenty":-8.797137,"median":9.425916,"eighty":38.597758,"marketCap":4033813516},{"date":"2024-01-12","current":23.423737,"twenty":-8.797137,"median":9.425916,"eighty":38.470225,"marketCap":4169425227},{"date":"2024-01-19","current":22.447867,"twenty":-8.804357,"median":9.30281,"eighty":38.332211,"marketCap":3995720339},{"date":"2024-01-26","current":22.718942,"twenty":-8.797137,"median":9.425916,"eighty":38.217781,"marketCap":4043971696},{"date":"2024-02-02","current":28.85349,"twenty":-8.797137,"median":9.425916,"eighty":38.049194,"marketCap":4731972377},{"date":"2024-02-09","current":27.918791,"twenty":-8.797137,"median":9.425916,"eighty":37.903318,"marketCap":4578681720},{"date":"2024-02-16","current":28.325049,"twenty":-8.797137,"median":9.425916,"eighty":37.631656,"marketCap":4645308051},{"date":"2024-02-23","current":28.413632,"twenty":-8.797137,"median":9.425916,"eighty":37.11978,"marketCap":4659835597},{"date":"2024-03-01","current":28.603015,"twenty":-8.789917,"median":12.47951,"eighty":32.879225,"marketCap":4690894489},{"date":"2024-03-08","current":29.339167,"twenty":-8.789917,"median":12.47951,"eighty":32.536971,"marketCap":4811623405},{"date":"2024-03-15","current":29.363604,"twenty":-8.789917,"median":12.47951,"eighty":32.258469,"marketCap":4815631004},{"date":"2024-03-22","current":29.357495,"twenty":-8.789917,"median":12.47951,"eighty":31.941046,"marketCap":4814629104},{"date":"2024-03-28","current":29.81568,"twenty":-8.789917,"median":12.47951,"eighty":31.40619,"marketCap":4889771583},{"date":"2024-04-05","current":29.122292,"twenty":-8.797137,"median":9.425916,"eighty":31.117622,"marketCap":4776055965},{"date":"2024-04-12","current":29.372767,"twenty":-8.797137,"median":9.425916,"eighty":31.051184,"marketCap":4817133853},{"date":"2024-04-19","current":29.168111,"twenty":-8.797137,"median":9.425916,"eighty":30.606254,"marketCap":4783570213},{"date":"2024-04-26","current":29.079528,"twenty":-8.789917,"median":12.47951,"eighty":30.256618,"marketCap":4769042667},{"date":"2024-05-03","current":24.879315,"twenty":-8.789917,"median":12.47951,"eighty":29.945905,"marketCap":4801707860},{"date":"2024-05-10","current":25.416952,"twenty":-8.789917,"median":12.47951,"eighty":29.757033,"marketCap":4905471669},{"date":"2024-05-17","current":25.614345,"twenty":-8.789917,"median":12.47951,"eighty":29.613467,"marketCap":4943568527},{"date":"2024-05-24","current":25.463703,"twenty":-8.789917,"median":12.47951,"eighty":29.5169,"marketCap":4914494609},{"date":"2024-05-31","current":25.87667,"twenty":-8.789917,"median":12.47951,"eighty":29.365437,"marketCap":4994197245},{"date":"2024-06-07","current":26.035104,"twenty":-8.789917,"median":12.47951,"eighty":29.342276,"marketCap":5024774986},{"date":"2024-06-14","current":25.292282,"twenty":-8.797137,"median":9.425916,"eighty":29.274986,"marketCap":4881410496},{"date":"2024-06-21","current":25.066319,"twenty":-8.804357,"median":9.30281,"eighty":29.230424,"marketCap":4837799620},{"date":"2024-06-28","current":24.487127,"twenty":-8.826676,"median":9.172548,"eighty":29.168722,"marketCap":4726015420},{"date":"2024-07-05","current":24.193634,"twenty":-8.826676,"median":9.172548,"eighty":29.132067,"marketCap":4669371408},{"date":"2024-07-12","current":24.601407,"twenty":-8.826676,"median":9.172548,"eighty":29.097856,"marketCap":4748071495},{"date":"2024-07-15","current":24.596212,"twenty":-8.826676,"median":9.172548,"eighty":29.090525,"marketCap":4747068946},{"date":"2024-08-02","current":24.957234,"twenty":-8.929025,"median":9.114705,"eighty":28.735731,"marketCap":4816746093},{"date":"2024-08-09","current":27.237695,"twenty":-8.929025,"median":9.114705,"eighty":28.677936,"marketCap":4058416549},{"date":"2024-08-16","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.593851,"marketCap":4159010197},{"date":"2024-08-23","current":28.407693,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4232746318},{"date":"2024-08-30","current":29.413827,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4382660153},{"date":"2024-09-06","current":28.273324,"twenty":-8.929025,"median":9.114705,"eighty":28.515633,"marketCap":4212725252},{"date":"2024-09-13","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.437936,"marketCap":4159010197},{"date":"2024-09-20","current":28.840298,"twenty":-8.929025,"median":9.114705,"eighty":28.414125,"marketCap":4297204384},{"date":"2024-09-27","current":28.584668,"twenty":-8.929025,"median":9.114705,"eighty":28.410315,"marketCap":4259115526},{"date":"2024-10-04","current":27.693241,"twenty":-8.929025,"median":9.114705,"eighty":28.328952,"marketCap":4126292846},{"date":"2024-10-11","current":27.781728,"twenty":-8.929025,"median":9.114705,"eighty":28.174035,"marketCap":4139477450},{"date":"2024-10-18","current":28.768197,"twenty":-8.929025,"median":9.114705,"eighty":28.155826,"marketCap":4286461373},{"date":"2024-10-25","current":27.847274,"twenty":-8.929025,"median":9.114705,"eighty":28.143107,"marketCap":4149243823},{"date":"2024-10-31","current":28.55845,"twenty":-8.929025,"median":9.114705,"eighty":28.102675,"marketCap":4255208977},{"date":"2024-11-08","current":23.317939,"twenty":-8.93818,"median":9.109339,"eighty":27.987673,"marketCap":3940731747},{"date":"2024-11-15","current":22.552233,"twenty":-8.93818,"median":9.109339,"eighty":27.96198,"marketCap":3811327297},{"date":"2024-11-22","current":21.642415,"twenty":-8.93818,"median":9.127228,"eighty":27.96083,"marketCap":3657568070},{"date":"2024-11-29","current":21.759491,"twenty":-8.93818,"median":9.172548,"eighty":27.96083,"marketCap":3677353987},{"date":"2024-12-06","current":21.310698,"twenty":-8.93818,"median":16.14628,"eighty":27.96083,"marketCap":3601507972},{"date":"2024-12-13","current":20.66399,"twenty":-8.93818,"median":16.326374,"eighty":27.96083,"marketCap":3492214336},{"date":"2024-12-20","current":20.056308,"twenty":-8.93818,"median":16.418565,"eighty":27.96083,"marketCap":3389516005},{"date":"2024-12-27","current":20.109271,"twenty":-8.93818,"median":16.564355,"eighty":27.96083,"marketCap":3398466777},{"date":"2025-01-03","current":19.440263,"twenty":-8.93818,"median":16.920255,"eighty":27.96083,"marketCap":3285404395},{"date":"2025-01-10","current":19.6399,"twenty":-8.938327,"median":17.089629,"eighty":27.96106,"marketCap":3319143109},{"date":"2025-01-17","current":19.75157,"twenty":-8.938327,"median":17.49484,"eighty":27.96106,"marketCap":3338015281},{"date":"2025-01-24","current":20.086579,"twenty":-8.938327,"median":17.759622,"eighty":27.96106,"marketCap":3394631794},{"date":"2025-01-31","current":-136.701619,"twenty":-9.032373,"median":17.86146,"eighty":27.96106,"marketCap":3007435623},{"date":"2025-02-07","current":-139.725612,"twenty":-9.144874,"median":17.86146,"eighty":27.96106,"marketCap":3073963459},{"date":"2025-02-14","current":-139.361017,"twenty":-9.245709,"median":17.86146,"eighty":27.96106,"marketCap":3065942372},{"date":"2025-02-21","current":-140.326121,"twenty":-9.301666,"median":17.86146,"eighty":27.96106,"marketCap":3087174660},{"date":"2025-02-28","current":-131.897546,"twenty":-9.377985,"median":17.86146,"eighty":27.96106,"marketCap":2901746013},{"date":"2025-03-07","current":-127.90845,"twenty":-9.455107,"median":17.87218,"eighty":27.96129,"marketCap":2813985889},{"date":"2025-03-14","current":-119.994597,"twenty":-9.579026,"median":17.87218,"eighty":27.96129,"marketCap":2639881128},{"date":"2025-03-21","current":-119.823023,"twenty":-9.954842,"median":17.87218,"eighty":27.96129,"marketCap":2636106499},{"date":"2025-03-28","current":-128.144364,"twenty":-10.210799,"median":17.87218,"eighty":27.96129,"marketCap":2819176004},{"date":"2025-04-04","current":-113.839378,"twenty":-10.377935,"median":17.87218,"eighty":27.96129,"marketCap":2504466314},{"date":"2025-04-11","current":-104.209785,"twenty":-10.499986,"median":17.86146,"eighty":27.96106,"marketCap":2292615264},{"date":"2025-04-17","current":-106.268673,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"marketCap":2337910812},{"date":"2025-04-25","current":-114.482781,"twenty":-10.734618,"median":17.87218,"eighty":27.96129,"marketCap":2518621173},{"date":"2025-05-02","current":-19.826576,"twenty":-10.796539,"median":17.87218,"eighty":27.96129,"marketCap":2240403051},{"date":"2025-05-09","current":-20.214777,"twenty":-10.804561,"median":17.87218,"eighty":27.96129,"marketCap":2284269804},{"date":"2025-05-16","current":-20.890086,"twenty":-10.804561,"median":17.87218,"eighty":27.96129,"marketCap":2360579678},{"date":"2025-05-23","current":-20.234996,"twenty":-10.804561,"median":17.87218,"eighty":27.96129,"marketCap":2286554531},{"date":"2025-05-30","current":-20.590847,"twenty":-10.804561,"median":17.87218,"eighty":27.96129,"marketCap":2326765722},{"date":"2025-06-06","current":-20.040895,"twenty":-10.804561,"median":17.87218,"eighty":27.96129,"marketCap":2264621154},{"date":"2025-06-13","current":-20.894129,"twenty":-10.804561,"median":17.87218,"eighty":27.96129,"marketCap":2361036623},{"date":"2025-06-20","current":-19.676956,"twenty":-10.798043,"median":17.87218,"eighty":27.96152,"marketCap":2223496073},{"date":"2025-06-27","current":-20.627241,"twenty":-10.798043,"median":17.87218,"eighty":27.96152,"marketCap":2330878230},{"date":"2025-07-03","current":-21.706926,"twenty":-10.798043,"median":17.87218,"eighty":27.96152,"marketCap":2452882638},{"date":"2025-07-11","current":-22.026383,"twenty":-10.798043,"median":17.87218,"eighty":27.96152,"marketCap":2488981321},{"date":"2025-07-18","current":-21.18528,"twenty":-10.798043,"median":17.87218,"eighty":27.96152,"marketCap":2393936688},{"date":"2025-07-25","current":-20.505928,"twenty":-10.798043,"median":17.87218,"eighty":27.96152,"marketCap":2317169869},{"date":"2025-08-01","current":-2.737049,"twenty":-10.76094,"median":17.87218,"eighty":27.96152,"marketCap":2356599194},{"date":"2025-08-08","current":-2.80022,"twenty":-10.723337,"median":17.87218,"eighty":27.96152,"marketCap":2410989284},{"date":"2025-08-15","current":-2.870292,"twenty":-10.566654,"median":17.87218,"eighty":27.96152,"marketCap":2471321149},{"date":"2025-08-22","current":-2.860736,"twenty":-10.421629,"median":17.87218,"eighty":27.96152,"marketCap":2463094076},{"date":"2025-08-29","current":-3.004596,"twenty":-10.277414,"median":17.87218,"eighty":27.96152,"marketCap":2586957222},{"date":"2025-09-05","current":-2.879316,"twenty":-10.005461,"median":17.87218,"eighty":27.96175,"marketCap":2479091161},{"date":"2025-09-12","current":-2.903204,"twenty":-9.719819,"median":17.87218,"eighty":27.96152,"marketCap":2499658843},{"date":"2025-09-19","current":-2.749789,"twenty":-9.45821,"median":17.87218,"eighty":27.96152,"marketCap":2367568624},{"date":"2025-09-26","current":-2.542228,"twenty":-9.436498,"median":17.87218,"eighty":27.96152,"marketCap":2188858328},{"date":"2025-10-03","current":-2.576733,"twenty":-9.32689,"median":17.87218,"eighty":27.96152,"marketCap":2218567201},{"date":"2025-10-10","current":-2.57461,"twenty":-9.261764,"median":17.87218,"eighty":27.96152,"marketCap":2216738963},{"date":"2025-10-17","current":-2.597967,"twenty":-9.173249,"median":17.87218,"eighty":27.96152,"marketCap":2236849584},{"date":"2025-10-24","current":-2.647336,"twenty":-9.074857,"median":17.87218,"eighty":27.96152,"marketCap":2279356125},{"date":"2025-10-31","current":-2.583634,"twenty":-8.91987,"median":17.87218,"eighty":27.96152,"marketCap":2224508975},{"date":"2025-11-07","current":-2.720181,"twenty":-3.003747,"median":17.87218,"eighty":27.96152,"marketCap":2298552627},{"date":"2025-11-14","current":-2.872173,"twenty":-2.952467,"median":17.87218,"eighty":27.96152,"marketCap":2426986369},{"date":"2025-11-21","current":-2.606744,"twenty":-2.890145,"median":17.87218,"eighty":27.96152,"marketCap":2202698684},{"date":"2025-11-28","current":-2.862116,"twenty":-2.871421,"median":17.87218,"eighty":27.96152,"marketCap":2418488177},{"date":"2025-12-05","current":-3.153738,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2664908806},{"date":"2025-12-12","current":-3.279801,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2771432010},{"date":"2025-12-19","current":-3.20676,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2709712557},{"date":"2025-12-26","current":-3.213253,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2715198731},{"date":"2026-01-02","current":-3.177352,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2684862348},{"date":"2026-01-09","current":-3.244506,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2741607351},{"date":"2026-01-16","current":-3.475212,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2936553892},{"date":"2026-01-23","current":-3.416723,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2887130825},{"date":"2026-01-30","current":-3.34307,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2824894371},{"date":"2026-02-06","current":-4.1748,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2888961309},{"date":"2026-02-13","current":-4.035926,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2792860901},{"date":"2026-02-20","current":-4.180751,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2893079898},{"date":"2026-02-27","current":-4.117928,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2849605904},{"date":"2026-03-06","current":-3.79389,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2625371619},{"date":"2026-03-13","current":-3.371318,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2332951807},{"date":"2026-03-20","current":-3.319075,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2296799748},{"date":"2026-03-24","current":-3.30122,"twenty":-2.870292,"median":17.87218,"eighty":27.96152,"marketCap":2284443982}],"updateTime":1774496037271},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASH\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","IE00B19Z4B17.USD","LU2463526074.USD","BK4006","LU0963586101.USD","LU2065731478.USD","BK4211","BK4161","BK4097","IE0031619046.USD","ASH","BK4187","BK4195","PFS","IE00B7SZL793.SGD","CR","CRS","IE00B66KJ199.SGD","ORR","OS"],"gpt_icon":0},{"id":"2590836615","title":"Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590836615","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590836615?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Dec.  08, 2025  (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positiv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201986/33289/en/Exicure-Presents-Positive-Topline-Phase-2-Data-for-Burixafor-in-Multiple-Myeloma-at-2025-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2590669123","title":"Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590669123","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590669123?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec.  08, 2025  (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of can","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201965/0/en/Cardiff-Oncology-Announces-Clinical-Data-from-Investigator-Sponsored-Trial-with-Onvansertib-in-Chronic-Myelomonocytic-Leukemia-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4109","LU2463526074.USD"],"gpt_icon":0},{"id":"2590633413","title":"Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590633413","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590633413?lang=en_us&edition=fundamental","pubTime":"2025-12-09 03:45","pubTimestamp":1765223100,"startTime":"0","endTime":"0","summary":"64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD  Encouraging safety/tolerability profile mainta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201903/0/en/Terns-Highlights-Additional-Positive-Phase-1-Clinical-Data-Supporting-TERN-701-s-Best-in-Disease-Potential-in-Relapsed-Refractory-CML-at-the-67th-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQQ9H92.USD","LU2211817866.USD","BK4588","LU2463526074.USD","LU1093756325.SGD","BK4567","LU1093756168.USD","BK4007","LU1721428933.USD","BK4548","LU2413666426.HKD","IE00BFXG0V08.USD","MTD","BK4109","LU0347712357.USD","TERN","BK4585","ASH","BK4533","BK4121","LU2413666699.HKD"],"gpt_icon":0},{"id":"2590368866","title":"Why Is Arcellx Stock Surging Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368866","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368866?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:23","pubTimestamp":1765218180,"startTime":"0","endTime":"0","summary":"Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SG9999015978.USD","BK4532","BK4588","IE00B7SZLL34.SGD","LU1430594728.SGD","LU0114720955.EUR","IE00B3T34201.USD","GILD","BK4583","IE00B19Z3581.USD","ASH","LU1674673691.USD","IE00BSNM7G36.USD","SG9999015986.USD","BK4195","IE00B19Z3B42.SGD","LU2324357040.USD","LU1066051498.USD","ACLX","LU1674673428.USD","BK4109","BK4211","LU0234570918.USD","BK4566","LU0889565916.HKD","LU1778281490.HKD","ORR","SG9999015952.SGD","SG9999015945.SGD","BK4097","LU2087621335.USD","BK4585","OS","PFS","LU1066053197.SGD","LU0320765992.SGD","LU0823416689.USD","LU2463526074.USD","IE0002270589.USD","BK4139","BK4578","LU1585245621.USD","LU0109394709.USD","LU0058720904.USD","LU0882574055.USD","LU1839511570.USD","LU1571399168.USD","LU0289739699.SGD","LU2089984988.USD","BK4550"],"gpt_icon":0},{"id":"1167606675","title":"Syndax Reports Strong Data for AML Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1167606675","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167606675?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:52","pubTimestamp":1765209128,"startTime":"0","endTime":"0","summary":"Shares of clinical-stage biopharmaceutical company Syndax Pharmaceuticals (SNDX) fell 3.2% in early Monday trading. The company presented updated data for its revumenib combination therapy at the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","SNDX","LU2463526074.USD","BK4139","BK4109"],"gpt_icon":0},{"id":"2589354927","title":"Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354927","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354927?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","OS","BK4139","PFS","BK4568","BK4097","CRVS","LU2463526074.USD","BK4195","BK4211","ASH"],"gpt_icon":0},{"id":"2589359079","title":"Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359079","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359079?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:27","pubTimestamp":1765204020,"startTime":"0","endTime":"0","summary":"Incyte Corporation  on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms  at the 2025 American Society of Hematology  Annual Meeting.The preliminary analysis  evaluated the safety and efficacy of INCA033989 in myelofibrosis  patients with as measured by spleen volume reduction ≥25%  and ≥35% , change in MPN-Symptom Assessment Form , total symptom score , anemia response and mutCALR variant allele frequency  reduction.Exploratory analyses from the clinical studies of INCA033989 demonstrate the potential for disease-modifying activity in MF patients with a CALR mutation, the company said in a press release.Also Read: FDA Expands Incyte’s Opzelura Approval To Treat Atopic Dermatitis In Children. In the monotherapy arms, patients treated with INCA033989 experienced rapid and robust spleen and anemia responses and symptom improvements.At Week 24, 41.7% of all evaluable patients achieved SVR25, and 33.3%  achieved SVR","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Konskie--Poland---December-08--2024-Incy.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Konskie--Poland---December-08--2024-Incy.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49256485/incytes-new-therapy-shows-signs-of-disease-modifying-potential-in-rare-blood-cancer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4561","BK4585","BK4588","LU2463526074.USD","BK4590","ET","BK4144","BK4550","INCY","TSS","BK4581","BK4139","ASH","BK4109","BK4532"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B66KJ199.SGD","BK4139","BK4132","LU0963586101.USD","BK4161","LU1699723380.USD","BK4585","CRS","BK4022","LU0985320562.USD","AFG","BK4123","BK4097","ALL","FC","IE00B7SZL793.SGD","BK4187","BK4533","LU2463526074.USD","BK4230","LU1571399168.USD","LU2065731478.USD","OS","BK4109","IE0031619046.USD","BK4539","IE00B19Z4B17.USD","ASH","BK4588","CR","BK4006","BK4117","UCL","BK4107","ORR","CAR","LU2355687059.USD","LENZ"],"gpt_icon":0},{"id":"2589355483","title":"Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355483?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200600,"startTime":"0","endTime":"0","summary":"Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201527/0/en/Ernexa-Therapeutics-Presents-New-Preclinical-Data-at-American-Society-of-Hematology-ASH-Annual-Meeting-on-Lead-Cell-Therapy-Candidate-for-Treatment-of-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ERNA","ASH","LENZ","BK4109","AFG","BK4007","BK4139","LU2463526074.USD","BK4107","BK4117"],"gpt_icon":0},{"id":"2589554843","title":"Vertex's Gene Therapy Works In Children With Blood Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2589554843","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589554843?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199880,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Incorporated  on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy  in patients aged 5 years and older with severe sickle cell disease  or transfusion-dependent beta thalassemia .SCD is a severe inherited blood disease that damages red blood cells, limits oxygen delivery, causes intense pain, and can shorten life.TDT is a life-threatening genetic condition that forces patients to rely on regular blood transfusions and lifelong treatment to remove excess iron.Also Read: FDA Fast-Tracks 6 More Drugs – Obesity And Cancer Drugs Included. In children with SCD, 11 patients have been dosed with Casgevy in the Phase 3 CLIMB-151 clinical study, and all (4/4) patients with sufficient follow-up achieved the primary endpoint of being free from vaso-occlusive crises  for at least 12 consecutive months .In children with TDT, 13 patients have been dosed with Casgevy in the Phase 3 CLIMB-141 clinical study, and all (6/6) patients with s","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Vertex-Pharmaceuticals-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Vertex-Pharmaceuticals-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49254689/vertexs-gene-therapy-works-in-children-with-blood-disorders","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49254689/vertexs-gene-therapy-works-in-children-with-blood-disorders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4567","SCD","BK4139","IE0002141913.USD","LU0289739699.SGD","LU1093756168.USD","LU1674673691.USD","LU0320765992.SGD","SG9999001176.SGD","IE00B2B36J28.USD","LU0109394709.USD","LU0432979614.USD","LU0058720904.USD","ASH","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU1069344957.HKD","IE00B19Z9Z06.USD","LU2462157665.USD","IE0002270589.USD","LU0061475181.USD","LU0234570918.USD","LU1778281490.HKD","SG9999013999.USD","BK4532","LU0823416689.USD","LU2463526074.USD","LU0889565916.HKD","LU1815336091.USD","IE0009355771.USD","LU2417539215.USD","VERX","BK4588","LU0566484027.USD","IE00BJT1NW94.SGD","LU2362541513.USD","LU1674673428.USD","IE00B894F039.SGD","LU1585245621.USD","IE00B19Z9P08.USD","LU0417517546.SGD","LU2324357040.USD","LU0256863811.USD","LU1093756325.SGD","SG9999001176.USD","VRTX","LU2237438978.USD","IE00BJJMRZ35.SGD","IE00BZ9MQY76.HKD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2589533799","title":"Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533799","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533799?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194600,"startTime":"0","endTime":"0","summary":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201378/0/en/Syndax-Highlights-Leadership-in-Menin-Inhibition-at-ASH-2025-with-Multiple-Revuforj-revumenib-Presentations-Spanning-the-Acute-Leukemia-Treatment-Continuum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","CR","HSCT","OS","BK4097","ASH","LU2355687059.USD","LU0985320562.USD","BK4129","ALL","ECG","BK4107","ORR","BK4533","BK4585","BK4109","BK4161","LU1699723380.USD","BK4588","LU2463526074.USD"],"gpt_icon":0},{"id":"2589828533","title":"ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589828533?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:30","pubTimestamp":1765175400,"startTime":"0","endTime":"0","summary":"Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201199/0/en/ASH-2025-Cellectis-Presents-Development-Plan-to-Further-Enhance-High-Response-Rate-Observed-for-Eti-cel-in-r-r-NHL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","BK4161","LU2463526074.USD","BK4139","ASH","BK4109","CR","ORR"],"gpt_icon":0},{"id":"2589388432","title":"Adaptive Biotechnologies (ADPT): Valuation Check After ASH clonoSEQ Data Spotlight and Q3 Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2589388432","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589388432?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:11","pubTimestamp":1765156272,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) is back in the spotlight as new clonoSEQ data dominates the American Society of Hematology meeting, just weeks after the company surprised Wall Street with stronger than expected third quarter profitability and revenue growth.\nSee our latest analysis for Adaptive Biotechnologies.\nDespite a sharp 1 day share price pullback of 15.52 percent to 14.75, Adaptive Biotechnologies still boasts a powerful year to date share price return of 138.29 percent and a 1 year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-valuation-check-after-ash-clon","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-valuation-check-after-ash-clon","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ASH","ADPT"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4203","BK4097","AAPG","BK4109","HR","BK4225","OS","ASH","ORR","BK4139"],"gpt_icon":0},{"id":"2589801826","title":"At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801826?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149300,"startTime":"0","endTime":"0","summary":"– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201155/0/en/At-ASH-2025-Oral-Presentation-Immix-Biopharma-Reports-Positive-Phase-2-NXC-201-Results-Advancing-Toward-BLA-Submission-as-a-Potentially-First-and-Best-in-Class-Therapy-for-relapsed.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4572","IE0034390439.USD","NXC","BK4104","LU2463526074.USD","BK4109","BK4161","CR","ODD","KOL","ASH","AL","BK4022","LU1169590202.USD","IE0009354923.USD","LU1169589451.USD","BK4183","IE00B19Z6F94.USD","CAR","BK4230"],"gpt_icon":0},{"id":"2589090158","title":"BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features","url":"https://stock-news.laohu8.com/highlight/detail?id=2589090158","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589090158?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:03","pubTimestamp":1765148580,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49248671/beone-medicines-announced-sonrotoclax-in-combination-with-brukinsa-demonstrated-rapid-mrd-negativity","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49248671/beone-medicines-announced-sonrotoclax-in-combination-with-brukinsa-demonstrated-rapid-mrd-negativity","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","LU2463526074.USD","BK4139","BK4526","ASH","ONC","BK4109","MDCO"],"gpt_icon":0},{"id":"2589809404","title":"SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809404","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809404?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:00","pubTimestamp":1765148400,"startTime":"0","endTime":"0","summary":"SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201154/0/en/SELLAS-Life-Sciences-Presents-Positive-Phase-2-Data-of-SLS009-in-Combination-with-AZA-VEN-in-Relapsed-Refractory-AML-MR-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASH","LU2463526074.USD","SLS","BK4109"],"gpt_icon":0},{"id":"2589773218","title":"Prime Medicine Announces The New England Journal of Medicine Publication of PM359  Clinical Data for the Treatment of Chronic Granulomatous Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2589773218","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589773218?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:05","pubTimestamp":1765112700,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec.  07, 2025  (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic thera","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201131/0/en/Prime-Medicine-Announces-The-New-England-Journal-of-Medicine-Publication-of-PM359-Clinical-Data-for-the-Treatment-of-Chronic-Granulomatous-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","CAC","BK4109","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMP","BK4211","BK4109","ALX","OS","BK4080","BK4124","LU2463526074.USD","BK4161","CR","BK4195","PFS","PR","ORR","BK4213","BK4231","BK4097","ASH"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":198,"code":"91000000","status":"200"}]}}